BioSpace News Archive

Transit Scientific announced it received CE Mark clearance in the European Union for the XO Score® Scoring Sheath Platform to facilitate dilation of stenotic material in the peripheral vasculature including popliteal, infrapopliteal, and native or synthetic arteriovenous dialysis fistulae.

NEAA’s current estimated annualized revenue run-rate is approximately US$3.6 million with operating EBITDA(1) margins equal to approximately 40% which is generally consistent with other similar acquisitions made by CRH.

New leadership includes Andrea Paul as general counsel and corporate secretary, and Janice Olson as senior vice president, strategy and portfolio management, bringing extensive experience in gene therapy and rare disease

Finerenone significantly reduced the risk of the composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus placebo when added to standard of care

BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, announced that three abstracts on BLU-5937 have been accepted for presentation at the upcoming American Thoracic Society 2021 International Conference, being held on May 14-19, 2021.

Orthofix Medical Inc., a global medical device company with a spine and orthopedics focus, announced expansion of its pediatric offerings with the U.S. Food and Drug Administration 510 clearance of the OrthoNext™ digital platform, the only software tool in the market for deformity analysis and preoperative planning for pediatric orthopedic procedures.

Intersect ENT, Inc., a global ear, nose and throat medical technology leader dedicated to transforming patient care, reported financial results for the first quarter ended March 31, 2021.

Study will evaluate maveropepimut-S (formerly known as DPX-Survivac) with an aromatase inhibitor, with/without radiotherapy or cyclophosphamide prior to surgery

The program recognizes community leaders whose work exemplifies best practices in supporting people with lung cancer in at-risk communities

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that Josh Bartch, CEO of Mydecine, will participate in the Benzinga Global Small Cap Conference to be hosted virtually on Thursday, May 13, 2021.